An update from Immunovant ( (IMVT) ) is now available.
Immunovant, Inc. reported promising results from its Phase 2a trial of batoclimab for treating Graves’ Disease, showing significant patient response rates and potential for the drug to be both first-in-class and best-in-class. The trial demonstrated a strong correlation between the reduction of IgG levels and clinical outcomes, indicating a substantial unmet need for patients uncontrolled on antithyroid drugs. With FDA alignment and Investigational New Drug Application clearance, Immunovant is poised to initiate a pivotal trial for its IMVT-1402 treatment by the end of the year, addressing a market with limited competition.
Learn more about IMVT stock on TipRanks’ Stock Analysis page.
